Chemomab Therapeutics Ltd (CMMB)

$1.08

-0.03

(-2.62%)

Market is closed - opens 7 PM, 16 Jul 2024

Performance

  • $1.08
    $1.19
    $1.08
    downward going graph

    0.0%

    Downside

    Day's Volatility :9.24%

    Upside

    9.24%

    downward going graph
  • $0.42
    $1.46
    $1.08
    downward going graph

    61.11%

    Downside

    52 Weeks Volatility :71.23%

    Upside

    26.03%

    downward going graph

Returns

PeriodChemomab Therapeutics Ltd
3 Months
63.46%
6 Months
97.8%
1 Year
-23.94%
3 Years
-94.11%

Highlights

Market Capitalization
15.8M
Book Value
$0.94
Earnings Per Share (EPS)
-1.54
Wall Street Target Price
5.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-48.23%
Return On Equity TTM
-93.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-20.4M
Diluted Eps TTM
-1.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-0.03
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Chemomab Therapeutics Ltd(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 425.0%

Current $1.08
Target $5.67

Technicals Summary

Sell

Neutral

Buy

Chemomab Therapeutics Ltd is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
27.07%
97.8%
-23.94%
-94.11%
-99.9%
Moderna, Inc.
Moderna, Inc.
-11.91%
18.91%
-0.91%
-57.59%
759.12%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.51%
15.45%
49.96%
85.53%
262.67%
Novo Nordisk A/s
Novo Nordisk A/s
0.73%
32.95%
75.69%
218.95%
492.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.62%
12.2%
37.12%
142.66%
178.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
NA
NA
NA
0.0
-0.94
-0.48
NA
0.94
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.58
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.45
32.45
1.46
44.24
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.59
49.59
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.74
31.74
0.53
17.07
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
Buy
$15.8M
-99.9%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
759.12%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$121.2B
262.67%
32.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$639.4B
492.58%
49.59
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.1B
178.64%
31.74
39.46%

Institutional Holdings

    Company Information

    chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).

    Organization
    Chemomab Therapeutics Ltd
    Employees
    0
    CEO
    Dr. Adi Mor George Ph.D.
    Industry
    Healthcare

    FAQs